National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Eptinezumab (Vyepti®). HTA ID: 22052

Eptinezumab is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month.


NCPE Assessment Process Complete
Rapid review commissioned 20/07/2022
Rapid review completed 16/09/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of eptinezumab (Vyepti®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.